Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $48.92 Average Price Target from Analysts

Scholar Rock Holding Corporation (NASDAQ:SRRK) has earned an average rating of “Buy” from the eighteen ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, thirteen have given a buy rating and four have given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $50.1429.

Several analysts recently commented on the stock. UBS Group initiated coverage on shares of Scholar Rock in a research report on Wednesday, January 7th. They set a “buy” rating and a $60.00 price target on the stock. Bank of America began coverage on Scholar Rock in a research report on Thursday, October 9th. They set a “buy” rating and a $53.00 target price on the stock. Truist Financial cut their price target on Scholar Rock from $54.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, October 20th. Wolfe Research began coverage on Scholar Rock in a research report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Wednesday, October 8th.

Scholar Rock Stock Up 0.4%

Shares of SRRK stock opened at $43.75 on Wednesday. Scholar Rock has a twelve month low of $22.71 and a twelve month high of $48.28. The stock has a market cap of $4.46 billion, a P/E ratio of -13.89 and a beta of 0.63. The stock has a 50 day moving average of $41.31 and a 200 day moving average of $36.74. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same period last year, the firm posted ($0.66) earnings per share. As a group, sell-side analysts expect that Scholar Rock will post -2.42 EPS for the current year.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, insider Mo Qatanani sold 136,462 shares of the company’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $45.21, for a total transaction of $6,169,447.02. Following the completion of the transaction, the insider directly owned 108,964 shares in the company, valued at approximately $4,926,262.44. This represents a 55.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $44.09, for a total transaction of $44,354.54. Following the completion of the sale, the director owned 32,908 shares in the company, valued at approximately $1,450,913.72. This trade represents a 2.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 13.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Scholar Rock

Several hedge funds and other institutional investors have recently made changes to their positions in SRRK. AQR Capital Management LLC boosted its holdings in Scholar Rock by 609.3% in the 1st quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock valued at $1,842,000 after purchasing an additional 49,217 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Scholar Rock by 12.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock valued at $1,709,000 after acquiring an additional 5,831 shares during the last quarter. Millennium Management LLC grew its position in Scholar Rock by 37.4% in the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after acquiring an additional 54,555 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Scholar Rock in the first quarter worth approximately $458,000. Finally, Jones Financial Companies Lllp acquired a new stake in Scholar Rock during the first quarter worth $1,159,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).